Shorts at 6%, page-3

I just can't see how the share price wouldn't spike on approval, particularly with the short squeeze as a result.

I suspect shorters are there more to profit from rejection, than hoping that approval won't lead to a price rise. If CUV get access to the US market then the current share price will look pretty cheap in a year or so once they hit full stride (probably less than that, given they'll be ready to pull the sales trigger immediately, and will likely have plenty of doctors/patients who are already aware of the product).